Sweden · Delayed Price · Currency is SEK Immunovia AB Statistics
Total Valuation
Immunovia AB has a market cap or net worth of SEK 135.21 million. The enterprise value is 79.60 million.
| Market Cap | 135.21M |
| Enterprise Value | 79.60M |
Important Dates
The next confirmed earnings date is Thursday, August 6, 2026.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Immunovia AB has 672.67 million shares outstanding. The number of shares has increased by 243.45% in one year.
| Current Share Class | 672.67M |
| Shares Outstanding | 672.67M |
| Shares Change (YoY) | +243.45% |
| Shares Change (QoQ) | +27.11% |
| Owned by Insiders (%) | 9.70% |
| Owned by Institutions (%) | 13.76% |
| Float | 607.39M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 146.96 |
| PB Ratio | 2.91 |
| P/TBV Ratio | 3.38 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 86.52 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.05, with a Debt / Equity ratio of 0.01.
| Current Ratio | 3.05 |
| Quick Ratio | 3.04 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -281.30% and return on invested capital (ROIC) is -130.92%.
| Return on Equity (ROE) | -281.30% |
| Return on Assets (ROA) | -91.30% |
| Return on Invested Capital (ROIC) | -130.92% |
| Return on Capital Employed (ROCE) | -171.96% |
| Weighted Average Cost of Capital (WACC) | 18.92% |
| Revenue Per Employee | 54,118 |
| Profits Per Employee | -6.27M |
| Employee Count | 17 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -53.58% in the last 52 weeks. The beta is 2.68, so Immunovia AB's price volatility has been higher than the market average.
| Beta (5Y) | 2.68 |
| 52-Week Price Change | -53.58% |
| 50-Day Moving Average | 0.20 |
| 200-Day Moving Average | 0.27 |
| Relative Strength Index (RSI) | 53.11 |
| Average Volume (20 Days) | 3,834,145 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Immunovia AB had revenue of SEK 920,000 and -106.56 million in losses. Loss per share was -0.24.
| Revenue | 920,000 |
| Gross Profit | 641,000 |
| Operating Income | -79.97M |
| Pretax Income | -106.56M |
| Net Income | -106.56M |
| EBITDA | -80.79M |
| EBIT | -79.97M |
| Loss Per Share | -0.24 |
Balance Sheet
The company has 56.09 million in cash and 479,000 in debt, with a net cash position of 55.61 million or 0.08 per share.
| Cash & Cash Equivalents | 56.09M |
| Total Debt | 479,000 |
| Net Cash | 55.61M |
| Net Cash Per Share | 0.08 |
| Equity (Book Value) | 46.50M |
| Book Value Per Share | 0.07 |
| Working Capital | 39.32M |
Cash Flow
| Operating Cash Flow | -74.93M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | -824,000 |
| Net Borrowing | -1.01M |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 69.67% |
| Operating Margin | -8,692.17% |
| Pretax Margin | -11,582.28% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Immunovia AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -243.45% |
| Shareholder Yield | -243.45% |
| Earnings Yield | -78.81% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Immunovia AB has an Altman Z-Score of -26.49 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -26.49 |
| Piotroski F-Score | 3 |